Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Sep;71(3):361-365.
doi: 10.1097/MPG.0000000000002815.

Safety of Rapid Infliximab Infusions in Children: A Systematic Review

Elsa A van Wassenaer  1 , Janneke P M van Oosterhout  1 , Joost G Daams  2 , Merlijn J M van den Berg  3 , Hanneke van der Lee  4   5 , Geert R D'Haens  6 , Tim G J de Meij  7 , Marc A Benninga  1 , Bart G P Koot  1
Affiliations

Safety of Rapid Infliximab Infusions in Children: A Systematic Review

Elsa A van Wassenaer et al. J Pediatr Gastroenterol Nutr. 2020 Sep.

Abstract

Objectives: The aim of the study was to assess whether the incidence of infusion reactions (IR) increases after rapid (≤1 hour) infliximab (IFX) infusions, compared with standard (2-3 hour) infusions in children.

Methods: Systematic review including studies describing the number of IR after rapid IFX infusion in children ages 0 to 18 years.

Results: Four records were included (3 retrospective, n = 498, 347 standard infusions, 3703 rapid infusions). Reported incidences of IR ranged from 0% to 2% of infusions in standard groups (reported 95% confidence intervals [CIs] ranged from 0% to 7%) and from 0% to 2% of infusions in rapid groups (reported 95% CIs ranged from 0% to 12%). None of the studies included reported a significant difference in incidence of IR between the 2 groups.

Conclusions: There is insufficient evidence to conclude whether the rate of IR after rapid IFX increases. The consistent finding of no increase in IR in all studies and the low rate of observed IR suggests there is no significant difference in rate of IR.

PubMed Disclaimer

Comment in

References

    1. Adler J, Sandberg KC, Shpeen BH, et al. Variation in infliximab administration practices in the treatment of pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2013; 57:35–38.
    1. Principi M, Losurdo G, La Fortezza RF, et al. Does infliximab short infusion have a beneficial impact on the quality of life in patients with inflammatory bowel diseases? A single centre prospective evaluation. J Gastrointest Liver Dis 2015; 24:165–170.
    1. Viola A, Costantino G, Privitera AC, et al. Clinical and economic impact of infliximab one-hour infusion protocol in patients with inflammatory bowel diseases: a multicenter study. World J Gastrointest Pharmacol Ther 2017; 8:131–136.
    1. Yeckes AR, Hoffenberg EJ. Rapid infliximab infusions in pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2009; 49:151–154.
    1. Doessegger L, Banholzer ML. Clinical development methodology for infusion-related reactions with monoclonal antibodies. Clin Transl Immunol 2015; 4:e39.

Publication types

LinkOut - more resources